Skip to main content
. 2016 Jun 15;5(6):e003270. doi: 10.1161/JAHA.116.003270

Table 1.

Characteristics of the Entire Study Group

No Sleep‐Disordered Breathing (n=115) Sleep‐Disordered Breathing (n=126) P Value
Age, y 63±12 64±12 0.755
Male, n (%) 83 (72) 102 (81) 0.145
Body mass index, kg/m2 24.3±3.6 25.9±4.1 0.006
Hypertension, n (%) 66 (57) 81 (64) 0.335
Dyslipidemia, n (%) 57 (50) 56 (44) 0.505
Diabetes mellitus, n (%) 35 (30) 49 (39) 0.215
Current smokers, n (%) 53 (46) 56 (44) 0.899
Previous myocardial infarction, n (%) 6 (5) 15 (12) 0.108
Estimated glomerular filtration rate, mL/min/1.73 m2 72.8 (31.7) 74.8 (26.6) 0.444
Type of acute coronary syndrome, n (%) 0.486
Unstable angina pectoris 18 (16) 14 (11)
Non–ST‐segment elevation myocardial infarction 14 (12) 13 (10)
ST‐segment elevation myocardial infarction 83 (72) 99 (79)
Culprit lesion, n (%) 0.667
Right coronary artery 48 (42) 54 (43)
Left circumflex artery 16 (14) 22 (18)
Left anterior descending artery 51 (44) 50 (40)
Thrombolysis in Myocardial Infarction flow before percutaneous coronary intervention, n (%) 0.017
0 67 (58) 96 (76)
1 13 (11) 6 (5)
2 16 (14) 8 (6)
3 19 (17) 16 (13)
Thrombolysis in Myocardial Infarction flow after percutaneous coronary intervention, n (%) 0.156
2 4 (3) 11 (9)
3 111 (97) 115 (91)
Peak creatine kinase, mg/dL 1246 (1988) 1774 (2497) 0.130
Left ventricular ejection fraction, % 58±10 53±12 0.002
Medications, n (%)
Dual antiplatelet therapy 98 (85) 115 (91) 0.206
Angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers 95 (84) 108 (86) 0.763
β‐Blockers 57 (50) 64 (51) 0.951
Calcium channel blockers 35 (30) 26 (21) 0.110
Statins 65 (57) 77 (61) 0.554
Oral hypoglycemic agents 13 (11) 25 (20) 0.101
Insulin injection 1 (1) 1 (1) 0.999

Data are presented as mean±SD or median (interquartile range) for continuous variables or number of patients (percentage) for categorical variables.